HPV testing with 16/18 genotyping for risk stratification among women with normal cytology: a multicenter prospective cohort study from China
Journal of Clinical Microbiology · 2026
DOI: 10.1128/jcm.01289-25 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Clinical Microbiology, 2026. Verfasst von Jiangong Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences, Northwestern Polytechnical University, Xi'an, China. Hauptthemen laut MEDLINE: Papillomavirus Infections, Human papillomavirus 18, Human papillomavirus 16, Genotyping Techniques. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
To evaluate the clinical performance of Hybribio’s 14-type HPV real-time PCR with 16/18 genotyping (HBRT-H14) and its risk stratification utility among women with normal cytology (NILM). From 2017 to 2020, a multicenter cohort enrolled 8,401 women aged 30–64 years with NILM cytology. Baseline HPV testing used HBRT-H14. Women positive for HPV 16/18 were referred for colposcopy; follow-up was annual for 3 years or until the detection of cervical intraepithelial neoplasia grade 2 or worse (CIN2+). Analyses included 6,679 women who completed follow-up. Overall HPV positivity was 11.4%, including 2.3% HPV 16/18. Over 3 years, sensitivity and specificity of HPV positivity for CIN2+ were 92.3% (95% confidence interval [CI]: 84.2–96.4) and 89.6% (88.8–90.3). For HPV 16/18 positivity, sensitivity and specificity were 41.0% (30.8–52.1) and 98.2% (97.8–98.5). Three-year cumulative CIN2+ risk was 20.9% (15.2–28.1) for HPV 16/18-positive women, 6.6% (4.9–8.9) for other types, and 0.1% (0.04–0.2) for HPV-negative women. HBRT-H14 shows strong clinical performance for detecting CIN2+, and HPV 16/18 genotyping provides effective risk stratification among women with NILM cytology. Findings support integration of HBRT-H14 into HPV-based screening pathways with HPV 16/18 genotyping and cytology triage of other types. IMPORTANCE This multicenter prospective study evaluated the Hybribio 14 high-risk HPV real-time PCR assay (HBRT-H14) in 8,401 women with normal (NILM) cytology under guideline-based follow-up. The assay showed high clinical sensitivity and a very low risk among HPV-negative women, and HPV 16/18 genotyping provided clear risk stratification. These findings deliver large-scale, practice-oriented evidence supporting integration of HBRT-H14 into HPV-based screening pathways that use HPV 16/18 genotyping with cytology triage of other types.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Life Sciences, Northwestern Polytechnical University, Xi'an, China.
- Department of Cancer Epidemiology and Prevention, Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Henan Engineering Research Center of Cancer Prevention and Control, Henan International Joint L…
- Department of Preventive Medicine, Changzhi Medical College, Changzhi, China.
- Department of Gynecology, Guangdong Women and Children Hospital, Guangzhou, China.
- Department of Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China.
- School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
ORCID-Profile: Hong Wang, Wen Chen, Shaokai Zhang, Hui Yang, Youlin Qiao
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhang, J., Wang, H., Liu, Y., Li, Z., Feng, X., Luo, X., Chen, W., Zhang, S., Yang, H., & Qiao, Y. (2026). HPV testing with 16/18 genotyping for risk stratification among women with normal cytology: a multicenter prospective cohort study from China. Journal of Clinical Microbiology. https://doi.org/10.1128/jcm.01289-25
Vancouver
Zhang J, Wang H, Liu Y, Li Z, Feng X, Luo X, et al. HPV testing with 16/18 genotyping for risk stratification among women with normal cytology: a multicenter prospective cohort study from China. Journal of Clinical Microbiology. 2026. doi:10.1128/jcm.01289-25
BibTeX
@article{Zhang2026,
author = {Zhang, Jiangong and Wang, Hong and Liu, Yin and Li, Zhifang and Feng, Xiangxian and Luo, Xiping and Chen, Wen and Zhang, Shaokai and Yang, Hui and Qiao, Youlin},
title = {HPV testing with 16/18 genotyping for risk stratification among women with normal cytology: a multicenter prospective cohort study from China},
journal = {Journal of Clinical Microbiology},
year = {2026},
doi = {10.1128/jcm.01289-25}
}
EUVIMED